Skip to main content

Advertisement

SpringerLink
Log in

Emerging Lipid-Lowering Therapies in Secondary Prevention

  • Secondary Prevention and Intervention (D. Steinberg, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The primary purpose of this article was to review the next-generation lipid-lowering therapies that are under current development and clinical testing. We reviewed the mechanism of action of these drugs and how they act on different pathways of lipid metabolism. Additionally, we aimed to present data from clinical trials evaluating clinical outcomes, efficacy, and safety of these novel agents. Lastly, we sought to provide recommendations for clinical practice and to comment on the cost-benefit analyses of such drugs.

Recent Findings

We evaluated the following lipid-lowering agents as they pertain to secondary prevention of atherosclerotic cardiovascular disease (ASCVD): ezetimibe, proprotein convertase subtilisin/kexin (PCSK) type 9 inhibitors, cholesteryl ester transfer protein inhibitors, and eicosapentaenoic acid ethyl ester. The two novel therapies currently approved by the US Food and Drug Administration and endorsed by the latest ACC/AHA cholesterol guidelines include ezetimibe and PCSK9 inhibitors. Although other drug classes have shown promising preliminary results, clinical trials evaluating cardiovascular outcomes are ongoing.

Summary

Patients with known ASCVD are at risk for recurrent ischemic events. Lipid-lowering therapies are an integral part of secondary prevention measures in such patients. There has been an upsurge in development of newer generation lipid-lowering therapies which have shown excellent results in preclinical studies. When added to statin therapy in high-risk patients or patients with suboptimal lipid profile despite statin therapy, these agents may significantly lower recurrent adverse cardiovascular events. Thorough cost-effectiveness simulations need to be performed prior to introduction of these agents in routine clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.

    Article  CAS  Google Scholar 

  2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.

    Article  Google Scholar 

  3. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178(5):576–84.

    Article  Google Scholar 

  4. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–8.

    Article  CAS  Google Scholar 

  5. Arnold SV, Kosiborod M, Tang F, Zhao Z, Maddox TM, McCollam PL, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation. 2014;129(12):1303–9.

    Article  CAS  Google Scholar 

  6. Maddox TM, Chan PS, Spertus JA, Tang F, Jones P, Ho PM, et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2014;63(6):539–46.

    Article  Google Scholar 

  7. Virani SS, Woodard LD, Akeroyd JM, Ramsey DJ, Ballantyne CM, Petersen LA. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014;37(11):653–9.

    Article  Google Scholar 

  8. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.

    Article  CAS  Google Scholar 

  9. • Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. This is a secondary prevention trial evaluating efficacy of the PCSK9 inhibitor, alirocumab, on cardiovascular outcomes.

    Article  CAS  Google Scholar 

  10. • Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. The FOURIER trial is one of the first randomized trials evaluating clinical efficacy and impact of PCSK9 inhibitors on background of statin therapy for secondary prevention of ASCVD events.

    Article  CAS  Google Scholar 

  11. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–40.

    Article  CAS  Google Scholar 

  12. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.

    Article  CAS  Google Scholar 

  13. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.

    Article  CAS  Google Scholar 

  14. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933–42.

    Article  Google Scholar 

  15. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406–15.

    Article  CAS  Google Scholar 

  16. Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27.

    Article  Google Scholar 

  17. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, plAcebo-controlled, randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–90.

    Article  CAS  Google Scholar 

  18. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–92.

    Article  CAS  Google Scholar 

  19. •• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1812792. The REDUCE-IT trial shows 25% risk reduction in major cardiovascular adverse events with the use of EPA on background of statin therapy.

    Article  CAS  Google Scholar 

  20. Altmann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–4.

    Article  CAS  Google Scholar 

  21. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8.

    Article  CAS  Google Scholar 

  22. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002;54(3):309–19.

    Article  CAS  Google Scholar 

  23. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43.

    Article  CAS  Google Scholar 

  24. •• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018, 2018. https://doi.org/10.1016/j.jacc.2018.11.003 This is the most recent 2018 ACC/AHA cholesterol guidelines.

  25. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515–24.

    Article  CAS  Google Scholar 

  26. Lepor NE, Kereiakes DJ. The PCSK9 inhibitors: a novel therapeutic target enters clinical practice. Am Health Drug Benefits. 2015;8(9):483–9.

    PubMed  PubMed Central  Google Scholar 

  27. McDonagh M, Peterson K, Holzhammer B, Fazio S. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm. 2016;22(6):641–53q.

    PubMed  Google Scholar 

  28. Yadav K, Sharma M, Ferdinand KC. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: present perspectives and future horizons. Nutr Metab Cardiovasc Dis. 2016;26(10):853–62.

    Article  CAS  Google Scholar 

  29. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115(9):1212–21.

    Article  CAS  Google Scholar 

  30. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.

    Article  CAS  Google Scholar 

  31. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9.

    Article  CAS  Google Scholar 

  32. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373–84.

    Article  CAS  Google Scholar 

  33. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). Circulation. 2018;137(4):338–50.

    Article  CAS  Google Scholar 

  34. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation. 2018;138(8):756–66.

    Article  CAS  Google Scholar 

  35. Giugliano RP, Sabatine MS, Ott BR. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(20):1997.

    Article  Google Scholar 

  36. Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, et al. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation. 2017;135(19):1819–31.

    Article  CAS  Google Scholar 

  37. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–9.

    Article  CAS  Google Scholar 

  38. Min S, Goldenberg N, Glueck C, Wang P. CRT-600.07 head to head efficacy of alirocumab 75 and 150 mg vs evolocumab 140 mg in real world patients. [abstract.]. J Am Coll Cardiol Intv. 2017;10(3 Suppl S):S53.

    Article  Google Scholar 

  39. Bai J, Gong LL, Li QF, Wang ZH. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: a meta-analysis of 11 randomized controlled trials. J Clin Lipidol. 2018;12(2):277–91.e3.

    Article  Google Scholar 

  40. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51.

    Article  CAS  Google Scholar 

  41. Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins. Circulation. 2018;138(13):1304–16.

    Article  CAS  Google Scholar 

  42. Stoekenbroek RM, Kallend D, Wijngaard PL, Kastelein JJ. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Futur Cardiol. 2018;14:433–42.

    Article  CAS  Google Scholar 

  43. Barter P, Rye KA. Cholesteryl ester transfer protein: its role in plasma lipid transport. Clin Exp Pharmacol Physiol. 1994;21(9):663–72.

    Article  CAS  Google Scholar 

  44. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 2004;101(1):17–38.

    Article  Google Scholar 

  45. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.

    Article  Google Scholar 

  46. Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, Dörries C, et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J. 2012;33(13):1615–24.

    Article  CAS  Google Scholar 

  47. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–80.

    Article  CAS  Google Scholar 

  48. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.

    Article  CAS  Google Scholar 

  49. Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem. 2014;60(5):737–46.

    Article  CAS  Google Scholar 

  50. Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131-3140. https://doi.org/10.1016/j.bbamem.2016.10.002.

    Article  CAS  Google Scholar 

  51. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.

    Article  CAS  Google Scholar 

  52. Virani SS, Akeroyd JM, Nambi V, Heidenreich PA, Morris PB, Nasir K, et al. Estimation of eligibility for proprotein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): insights from the Department of Veterans Affairs. Circulation. 2017;135(25):2572–4.

    Article  Google Scholar 

  53. Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(9):959–66.

    Article  Google Scholar 

  54. Hlatky MA, Kazi DS. PCSK9 inhibitors: economics and policy. J Am Coll Cardiol. 2017;70(21):2677–87.

    Article  CAS  Google Scholar 

  55. • Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(10):1069–78. This study shows cost-benefit analysis in terms of additional price per quality adjusted life year with the use of PCSK9 inhibitors in patients with cardiovascular disease.

    Article  Google Scholar 

  56. Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39(6):313–20.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Florida, Gainesville, FL, USA

    Dhruv Mahtta & Anthony A. Bavry

  2. Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

    Salim S. Virani

  3. Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    Salim S. Virani

  4. Medical Service, Cardiology Section (111D), North Florida/South Georgia Veterans Health System (Malcom Randall Veterans Administration Medical Center), 1601 SW Archer Road, Gainesville, FL, 32608, USA

    Anthony A. Bavry

Authors
  1. Dhruv Mahtta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salim S. Virani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony A. Bavry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony A. Bavry.

Ethics declarations

Conflict of Interest

Dr. Dhruv Mahtta and Dr. Anthony A. Bavry declare that they have no conflict of interest. Dr. Salim S. Virani: research support: VA Health Services Research and Development, American Heart Association, American Diabetes Association, and research fund from Drs. Abida and Nuruddin Jooma. Dr. Virani also serves on the steering committee for the Patient and Provider Assessment of Lipid Management (PALM) registry at the Duke Clinical Research Institute (DCRI) (no financial remuneration).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Secondary Prevention and Intervention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahtta, D., Virani, S.S. & Bavry, A.A. Emerging Lipid-Lowering Therapies in Secondary Prevention. Curr Cardiovasc Risk Rep 13, 11 (2019). https://doi.org/10.1007/s12170-019-0607-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-019-0607-z

Keywords

Search

Navigation